Melanoma Immunotherapy Nears the Finish Line: FDA Approves Registration Phase 3 Trial of iSCIB1+
FDA has authorized the start of the pivotal Phase 3 clinical trial of iSCIB1+ for the treatment of advanced melanoma. The decision is based on impressive Phase 2 results, where the new DNA vaccine showed a 24% improvement in progression-free survival compared to standard therapy.
Melanoma Immunotherapy Nears the Finish Line: What's Behind the Success of iSCIB1+ and When to Expect Approval
Introduction
In late April 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to iSCIB1+ for the treatment of advanced melanoma. This decision, following the January approval of an Investigational New Drug (IND) application for the registration Phase 3, establishes a clear regulatory pathway for the first-in-class DNA vaccine against melanoma. Behind these regulatory steps lie data that even skeptical oncologists call "game-changing": 74% progression-free survival at 16 months versus 50% with the current standard of care.
Event Details and Timeline
The timeline for iSCIB1+ reaching the finish line spanned the first half of 2026. In January, the FDA approved the IND application for a global registration Phase 3 study. In April, it added Fast Track Designation, which ensures more frequent interaction with the regulator and opens the door to accelerated approval and priority review in the future. Phase 3 itself is scheduled for the second half of 2026, with potential commercialization by 2029.
The basis for these decisions came from the SCOPE study—a multi-group, open-label, multicenter Phase 2 trial involving 140 patients with unresectable stage IIIB/IV melanoma. The key cohort was Cohort 3, where iSCIB1+ was added to standard dual checkpoint inhibitor therapy (nivolumab plus ipilimumab) in patients with specific human leukocyte antigen (HLA) alleles, representing approximately 80% of all melanoma patients.
The numbers are impressive. Progression-free survival (PFS) in the target population was 74% at 16 months and 77% at 20 months. For comparison, the historical control in the CheckMate 067 study showed 50% PFS at 11.5 months for the combination of ipilimumab and nivolumab without the vaccine. In essence, adding iSCIB1+ increased progression-free time by 24 percentage points.
Subgroup data are equally important. The effect was maintained in patients with low PD-L1 expression, wild-type BRAF, and those who had previously received checkpoint inhibitors—populations that historically have worse outcomes on standard therapy. The overall response rate in pooled Cohorts 1 and 3 was 68.6%, complete response 17.9%, and disease control 88%. For context, the historical response rate in CheckMate 067 was about 50%.
At the core of the drug is the ImmunoBody platform. iSCIB1+ is a DNA plasmid encoding six melanoma epitopes, prompting the patient's own cells to generate a tumor-specific T-cell response. Translational data show that all six epitopes generate targeted T-cell responses, and CD8+ T-cell responses are associated with 83% clinical response and the formation of memory T-cells. The vaccine is administered via a needle-free intramuscular injector—a solution that reduces patient discomfort and eliminates risks associated with sharp medical waste disposal.
Impact and Significance
The significance of iSCIB1+'s advancement unfolds across four dimensions: therapeutic, economic, regulatory, and scientific.
Therapeutic Shift. Melanoma remains one of the deadliest skin cancers: approximately 325,000 new cases are diagnosed worldwide each year, and about 58,000 patients die. The first-line standard—dual checkpoint blockade—yields a response in only half of patients, and about 50% of them are refractory or relapse quickly. Five-year survival for stage IV is less than 23%. Adding a DNA vaccine that boosts PFS by more than 20 percentage points without potentiating toxicity is exactly what the field has been seeking for a decade.
Economic Potential. Analysts estimate the target market for iSCIB1+ at $3 billion for advanced melanoma and up to $6–9 billion including neoadjuvant and adjuvant use. For Scancell, with a current market capitalization of about $162.72 million (as of March 2026), this is a transformative drug. However, the company operates with a limited cash runway—funds last until the second half of 2026, and management is actively evaluating partnership and financing options to continue development.
Regulatory Precedent. The FDA agreed to use progression-free survival as a surrogate endpoint for the registration study. This is an unconventional but strategically sound decision: it accelerates data collection and reduces reliance on overall survival, which in melanoma with effective standard therapy requires years of follow-up. Fast Track status adds flexibility: accelerated approval, priority review, and rolling submission become available.
Scientific Significance. iSCIB1+ is not a checkpoint inhibitor or a traditional peptide- or dendritic cell-based vaccine. It is a DNA plasmid that, after intramuscular injection, prompts the patient's cells to produce an antibody-epitope construct targeting dendritic cells and generating a potent T-cell response against the tumor. The success of this platform paves the way for similar approaches in other solid tumors—Scancell's pipeline already includes Modi-1 for a broad range of solid tumors in Phase 2.
Key Stakeholder Reactions
The developer's reaction is understandably positive. Scancell CEO Phil L'Huillier called the Fast Track designation "a major achievement and an important recognition of the potential of iSCIB1+, as well as the significant unmet need for new treatment options for patients with advanced melanoma." He added, "The SCOPE data show a significant improvement in progression-free survival, as well as emerging signals for overall survival compared to historical benchmarks."
Financial markets react to Scancell news with cautious optimism. The company ended the first half of fiscal 2026 with cash of £8.6 million (about $10.9 million at current exchange rates) and a net loss of £5.7 million. Operating expenses are controlled, and additional tax credits of £3 million were received after the reporting date. The key question is funding for Phase 3: management states it is "actively evaluating partnership and financing options," which in biotech parlance means either a licensing deal with a large pharma or an equity offering.
Independent analysts point to several strategic risks. The choice of control group for Phase 3 is critical: many U.S. centers are switching from ipilimumab plus nivolumab to nivolumab plus relatlimab for safety and convenience. If the control group uses a more modern regimen, historical comparisons lose relevance. Additionally, HLA typing as an inclusion criterion adds logistical complexity: sites must arrange centralized testing, which could slow enrollment and increase screening failures.
Forecast and Conclusions
The advancement of iSCIB1+ sets several key trends in immuno-oncology.
First—the return of therapeutic vaccines to the mainstream. After a decade of disappointments, where dozens of melanoma vaccines failed in late phases, the DNA plasmid approach with HLA-based patient selection may succeed. If Phase 3 confirms the SCOPE results, it will usher in an era of "off-the-shelf" DNA immunotherapy.
Second—precision in immuno-oncology. Enriching the study through HLA selection is a double-edged sword: on one hand, it increases statistical power and effect size; on the other, it narrows the population and complicates real-world implementation. If successful, this approach will become a model for future trials.
Third—regulatory evolution. Using PFS as a surrogate endpoint in melanoma is not new, but agreeing on this parameter for a registration study of an adjuvant vaccine signals the FDA's readiness for flexible designs that accelerate patient access to innovative therapies.
Fourth—financing will determine speed. Scancell, with a market cap of about $163 million, is attempting to navigate a registration path that costs hundreds of millions of dollars alone. A partnership with a major player is the most likely scenario, and the terms of such a partnership will signal to the entire industry how much Big Pharma believes in the ImmunoBody platform.
Open questions remain. Overall survival data will not be available until 2027. The long-term safety of the DNA vaccine in combination with highly toxic dual checkpoint blockade needs confirmation. Reproducibility of the effect when scaling from a single centralized SCOPE study to a global Phase 3 is always a challenge. Finally, the lack of randomized control in Phase 2 leaves room for skepticism: cross-trial comparisons with historical CheckMate 067 data are informative but do not replace direct comparison within a single protocol.
In summary: January–April 2026 will go down in melanoma immunotherapy history as the moment when the DNA vaccine iSCIB1+ moved from "promising early phase" to "drug with a clear path to registration." Seventy-four percent progression-free survival at 16 months is not just a number. It is the translation of complex immunology into clinical benefit for patients who previously had only a little over 50% chance of one-year disease control. The registration Phase 3 starts in the second half of the year, with additional PFS and early overall survival data expected in 2027. If the trend holds, oncologists will have a first-in-class drug that not only inhibits the immune system's "brakes" but precisely teaches it to recognize and destroy melanoma.
— Editorial Team
